{"id":777221,"date":"2025-12-02T03:25:02","date_gmt":"2025-12-02T03:25:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=777221"},"modified":"2025-12-02T03:25:02","modified_gmt":"2025-12-02T03:25:02","slug":"global-biomarkers-market-forecast-reaching-10415-billion-by-2030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/global-biomarkers-market-forecast-reaching-10415-billion-by-2030_777221.html","title":{"rendered":"Global Biomarkers Market Forecast: Reaching $104.15 Billion by 2030"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/upload\/2025\/12\/1764589562.jpg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Global Biomarkers Market Forecast: Reaching $104.15 Billion by 2030\" src=\"https:\/\/www.abnewswire.com\/upload\/2025\/12\/1764589562.jpg\" alt=\"Global Biomarkers Market Forecast: Reaching $104.15 Billion by 2030\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>By PCR technology, the biomarkers market is segmented by technology into immunoassays, NGS, PCR, mass spectrometry, chromatography, and other technologies. PCR technology, which is used for detecting, quantifying, and validating nucleic acid-based biomarkers, is estimated to register the highest CAGR during the forecast period of 2025-2030. <\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">The global Biomarkers Market, valued at US$58.07 billion in 2024 stood at US$62.39 billion in 2025 and is projected to advance at a resilient CAGR of 10.8% from 2025 to 2030, culminating in a forecasted valuation of US$104.15 billion by the end of the period.<\/div>\n<p style=\"text-align: justify;\">The <strong>global <\/strong><a rel=\"nofollow\" href=\"https:\/\/www.marketsandmarkets.com\/Market-Reports\/biomarkers-advanced-technologies-and-global-market-43.html\"><strong>biomarkers market<\/strong><\/a> is undergoing a rapid transformation, driven by advances in <strong>drug development, precision medicine, and companion diagnostics.<\/strong> Valued at <strong>US$58.07 billion in 2024<\/strong>, the market reached <strong>US$62.39 billion in 2025<\/strong> and is projected to grow at a robust <strong>CAGR of 10.8% from 2025 to 2030<\/strong>, reaching <strong>US$104.15 billion<\/strong> by the end of the forecast period. This exponential rise underscores the critical role biomarkers play in enabling <strong>personalized treatment pathways, early disease detection, and clinical decision-making.<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Market Growth Insights &amp; Trends<\/strong><\/p>\n<p style=\"text-align: justify;\">Biomarkers have become essential tools in <strong>healthcare innovation<\/strong>. Their use in <strong>oncology, neurology, cardiology, and infectious diseases<\/strong> is reshaping diagnostics and therapeutics.<\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Market Size &amp; Forecast:<\/strong> $62.39 billion in 2025 &rarr; $104.15 billion by 2030.<\/li>\n<li><strong>Growth Drivers:<\/strong> Increasing adoption of <strong>companion diagnostics<\/strong> and expansion of <strong>clinical trials leveraging biomarker data<\/strong>.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.marketsandmarkets.com\/pdfdownloadNew.asp?id=43\"><strong>Download an Illustrative overview: <\/strong><\/a><\/p>\n<p style=\"text-align: justify;\"><strong>Key Market Drivers<\/strong><\/p>\n<p style=\"text-align: justify;\">Several forces are propelling the <strong>biomarkers market growth<\/strong>:<\/p>\n<ol style=\"text-align: justify;\">\n<li><strong>Rising Role of Companion Diagnostics<\/strong> &ndash; Biomarkers are central to tailoring therapies for individual patients, especially in oncology.<\/li>\n<li><strong>Advancements in Precision Medicine<\/strong> &ndash; The demand for patient-specific treatment approaches continues to expand.<\/li>\n<li><strong>Drug Development &amp; Clinical Trials<\/strong> &ndash; Pharmaceutical companies increasingly rely on biomarkers to identify responders, reduce trial costs, and improve approval timelines.<\/li>\n<li><strong>Technological Innovations<\/strong> &ndash; Integration of <strong>AI, next-gen sequencing, and bioinformatics<\/strong> in biomarker research is accelerating discoveries.<\/li>\n<\/ol>\n<p style=\"text-align: justify;\"><strong>Challenges &amp; Opportunities<\/strong><\/p>\n<p style=\"text-align: justify;\">Despite strong growth, the biomarkers market faces obstacles:<\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Regulatory Hurdles<\/strong> &ndash; Complex approval processes can delay biomarker commercialization.<\/li>\n<li><strong>High R&amp;D Costs<\/strong> &ndash; Developing biomarker assays requires substantial investment.<\/li>\n<li><strong>Data Standardization Issues<\/strong> &ndash; Harmonization of biomarker data across clinical settings remains limited.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">However, opportunities abound in:<\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Liquid Biopsies<\/strong> &ndash; Non-invasive diagnostics are emerging as game changers.<\/li>\n<li><strong>Biomarker-Based Therapies<\/strong> &ndash; Accelerating demand in <strong>oncology, rare diseases, and autoimmune conditions<\/strong>.<\/li>\n<li><strong>Global Collaborations<\/strong> &ndash; Partnerships between pharma, biotech, and diagnostic companies are shaping the next wave of innovations.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Competitive Landscape<\/strong><\/p>\n<p style=\"text-align: justify;\">The biomarkers market is highly competitive, with global players investing heavily in <strong>R&amp;D, partnerships, and acquisitions.<\/strong> Major companies include:<\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Roche Diagnostics<\/strong><\/li>\n<li><strong>Thermo Fisher Scientific<\/strong><\/li>\n<li><strong>Abbott Laboratories<\/strong><\/li>\n<li><strong>Siemens Healthineers<\/strong><\/li>\n<li><strong>Bio-Rad Laboratories<\/strong><\/li>\n<li><strong>Qiagen N.V.<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">These companies are focusing on <strong>expanding biomarker assays, advancing companion diagnostics, and leveraging AI in biomarker discovery.<\/strong><\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.marketsandmarkets.com\/requestsampleNew.asp?id=43\"><strong>Request Sample Pages: <\/strong><\/a><\/p>\n<p style=\"text-align: justify;\"><strong>Future Outlook: Biomarkers Market 2030<\/strong><\/p>\n<p style=\"text-align: justify;\">Looking ahead, the <strong>biomarkers industry forecast<\/strong> points toward a future shaped by:<\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Wider adoption of digital biomarkers<\/strong> for remote monitoring and chronic disease management.<\/li>\n<li><strong>Next-generation sequencing (NGS) biomarkers<\/strong> integrated with clinical workflows.<\/li>\n<li><strong>Increased role in preventive healthcare<\/strong> with early detection and risk assessment models.<\/li>\n<li><strong>AI-powered biomarker discovery platforms<\/strong> reducing research timelines and costs.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">By 2030, biomarkers will not just support diagnostics but become the backbone of <strong>global precision medicine.<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Conclusion <\/strong><\/p>\n<p style=\"text-align: justify;\">The <strong>biomarkers market<\/strong> is on track to surpass <strong>US$104 billion by 2030<\/strong>, fueled by breakthroughs in <strong>drug development, diagnostics, and precision medicine.<\/strong> Companies that invest in <strong>innovation, partnerships, and data-driven biomarker research<\/strong> will be best positioned to capitalize on this rapidly evolving market.<\/p>\n<p style=\"text-align: justify;\">For <strong>healthcare innovators, biotech leaders, and investors<\/strong>, now is the time to explore opportunities in the <strong>global biomarkers industry.<\/strong><\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.marketsandmarkets.com\/requestCustomizationNew.asp?id=43\"><strong>Get 10% Free Customization on this Report<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\"><strong>Frequently Asked Questions (FAQs)<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>1. What is driving the growth of the biomarkers market?<\/strong> The key drivers include rising demand for <strong>precision medicine, growing use of companion diagnostics, and biomarker-based drug development.<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>2. How big is the biomarkers market expected to be by 2030?<\/strong> The market is projected to reach <strong>US$104.15 billion by 2030<\/strong>, growing at a <strong>CAGR of 10.8%<\/strong> from 2025.<\/p>\n<p style=\"text-align: justify;\"><strong>3. Which industries benefit the most from biomarkers?<\/strong> Pharmaceuticals, biotechnology, diagnostics, and clinical research organizations (CROs) are the main beneficiaries.<\/p>\n<p style=\"text-align: justify;\"><strong>4. Who are the major players in the biomarkers market?<\/strong> Key players include <strong>Roche, Thermo Fisher Scientific, Abbott, Siemens Healthineers, Bio-Rad, and Qiagen.<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>5. What role do biomarkers play in precision medicine?<\/strong> Biomarkers enable <strong>personalized treatment pathways, better patient stratification, and targeted therapy development.<\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/marketsandmarkets.com_145966.html\" rel=\"nofollow\">MarketsandMarkets\u2122 Research Private Ltd.<\/a><br \/><strong>Contact Person:<\/strong> Mr. Rohan Salgarkar<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=global-biomarkers-market-forecast-reaching-10415-billion-by-2030\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 18886006441<br \/><strong>Address:<\/strong>1615 South Congress Ave.  Suite 103, Delray Beach, FL 33445<br \/><strong>City:<\/strong> Florida<br \/><strong>State:<\/strong> Florida<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.marketsandmarkets.com\/Market-Reports\/biomarkers-advanced-technologies-and-global-market-43.html\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.marketsandmarkets.com\/Market-Reports\/biomarkers-advanced-technologies-and-global-market-43.html<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=global-biomarkers-market-forecast-reaching-10415-billion-by-2030\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>By PCR technology, the biomarkers market is segmented by technology into immunoassays, NGS, PCR, mass spectrometry, chromatography, and other technologies. PCR technology, which is used for detecting, quantifying, and validating nucleic acid-based biomarkers, is estimated to register the highest CAGR &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/global-biomarkers-market-forecast-reaching-10415-billion-by-2030_777221.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,406,403,404,416],"tags":[],"class_list":["post-777221","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-UK","category-US","category-World"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/777221","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=777221"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/777221\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=777221"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=777221"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=777221"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}